Conclusion
In patients with schizophrenia, haloperidol is better than placebo for global improvement but increases the rates of parkinsonism, akathisia, and acute dystonias substantially. *See Review: haloperidol decanoate is superior to placebo for schizophrenia [abstract] . Evidence-Based Mental Health 1999 Aug; 2:84. website extra 
Weighted mean scores Weighted mean difference (CI)
Mean BPRS score 6 weeks (2) 26.4 38.3 11.9 (6.7 to 17.0) †BPRS=Brief Psychiatric Rating Scale; GI=marked global improvement; NR=data not reported; RCTs=randomised controlled trials. Other abbreviations defined in glossary; mean follow up, weighted event rates, weighted mean scores, RRR, RRI, NNT, NNH, and CI calculated from data in article. ‡Unweighted data. §Data reported in article.
COMMENTARY
Haloperidol has played a pivotal role in the treatment of psychosis. It has been widely used in developed and developing countries and, until recently, was the "industry standard" against which newer medications were compared. In addition to quantifying long standing clinical impressions, this scholarly review by Joy et al reminds us of some sobering clinical facts about the treatment of schizophrenia. Although haloperidol was found to be superior to placebo for the treatment of schizophrenia, many people with the condition did not make an immediate nor complete recovery. Rates of extrapyramidal adverse effects were very high (put more bluntly, unacceptably high). Unfortunately, the authors did not proceed with a planned sensitivity analysis examining safety and efficacy of haloperidol at different doses compared with placebo. Although little doubt exists that higher doses of traditional antipsychotics are associated with higher rates of extrapyramidal symptoms (EPS), we need more information on the safety and efficacy of low dose traditional antipsychotic medication.
A recent systematic review comparing traditional antipsychotic medication (including haloperidol) with newer medications (the "atypicals") suggested that the often quoted superior side effect profile of newer medications is attenuated when the dose of the comparator medication is in the lower range.
1 A related Cochrane review is currently underway comparing different doses of haloperidol. Clinicians need advice about the safety and efficacy of low dose haloperidol to make an informed decision about the use of this product and newer medications. For example, newer medications tend be associated with substantial weight gain, which can contribute to long term comorbidity.
2 Clinicians need quality data to balance the risks and benefits of low dose traditional antipsychotics compared with newer atypical antipsychotics (which are associated with more weight gain, but fewer EPS). 
